# Hanne Capital

> Hanne Capital is a VC fund in Shanghai backing Biotechnology and Health Care. See 14 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Shanghai, China
- Total investments: 14
- Last investment: May 2022
- Lead investor: 64%
- Fund size: $100M
- Last fund: Sep 2019
- Last updated: Aug 2026
- Website: http://www.hannecapital.com/

Hanne Capital is a healthcare venture capital fund focusing on growth opportunities in the Greater China.

## Contacts

5 contacts available for Hanne Capital. Shizune tracks 1 team members at Hanne Capital. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/hanne-capital?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 8 | 57% |
| Health Care | 5 | 36% |
| Pharmaceutical | 3 | 21% |
| Biopharma | 2 | 14% |
| Manufacturing | 2 | 14% |

10 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 5 | 36% |
| Series B | 5 | 36% |
| Series C | 3 | 21% |
| Angel | 1 | 7% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| China | 8 | 57% |
| France | 1 | 7% |
| United States | 1 | 7% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Edward Zhou | Founder & Managing Partner | 0 | https://shizune.co/investors/profile/edward-zhou-4b2b |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Reistone Biopharma | Reistone Biopharma is a clinical stage biopharmaceutical company. It is focused on rapidly developing innovative medicines through global collaborations within Research and Development | $100M | Series A | May 09, 2022 |  |
| KYinno | KYinno is a drug development company that is dedicated to oncology drug development with a focus on immune treatments against cancer. | $9.3M | Series A | Jan 08, 2021 |  |
| BioNova Pharma | Biopharma company for cancer medicine | $25M | Series B | Oct 20, 2020 |  |
| FRESH WIND GROUP HOLDING LIMITED | Cell Therapy | $30M | Series A | Sep 01, 2020 |  |
| Celula China | Celula China focus on product developments in flow cytometry, FCM reagents, NIPT reagents and other related products. | $7.1M | Series B | Sep 01, 2020 |  |
| Celula | celula specializes in R&D and production of clinical equipment like flow cytometry and supporting reagents & non-invasive prenatal testing. | $7.3M | Series B | Sep 01, 2020 |  |
| IMVAQ Therapeutics | Imvaq Therapeutics is an innovative cancer immunotherapy company. | $20M | Series B | Aug 31, 2020 |  |
| Biotheus | Biotheus is an up-and-coming biotech company focused on curing malignant tumors and autoimmune diseases. Biotheus is committed to research and development, and commercialization of first-class innovative biologics mainly through the discovery of next-generation multispecific antibodies. | $5M | Series C | Jun 29, 2020 |  |
| EOC Pharma Group | EOC Pharma is an integrated biopharmaceutical company that is focused on the manufacturing, development and commercialization of innovative global oncology products in China. They have adopted a licensing model in order to build EOC’s innovative pipeline by plugging their partner’s molecule into EOC’s “core engine” of local manufacturing,clinical development, regulatory filing, and commercialization. The company has a pipeline of seven novel products from global biopharmaceutical partners that are potentially first- and best-in-class. Until now, EOC has obtained four Class I innovative drug CTA approvals and initiated clinical studies of four lead products in China.,EOC has a team of entrepreneurs and consultants with overseas background that boasts of first-class pharmaceutical R&D expertise as well as rich industry experience. The company owns an 8,000 square meter cGMP manufacturing facility in Taizhou, China Medical City and has offices in Shanghai, Beijing, Hong Kong and Los Angeles.EOC will leverage forward-looking licensing which will provide product opportunities to their integrated platform, generating a highly strategic portfolio. Ultimately, this will position EOC at the top of oncology innovation in China. | $70.9M | Series C | Dec 02, 2019 |  |
| Ningkang Ruizhu | Ningkang Ruizhu is a targeted drugs developer. | $10M | Series A | Sep 27, 2019 |  |

10 of 14 investments shown.

## Co-investors
- [BioVenture](https://shizune.co/investors/profile/bioventure) — VC Fund, 2 deals together
- [Hengqin Financial Investment](https://shizune.co/investors/profile/hengqin-financial-investment) — VC Fund, 2 deals together
- [BioTrack Capital](https://shizune.co/investors/profile/biotrack-capital) — VC Fund, 1 deal together
- [Capital Healthcare Fund](https://shizune.co/investors/profile/capital-healthcare-fund) — VC Fund, 1 deal together
- [Delian Capital](https://shizune.co/investors/profile/delian-capital) — VC Fund, 1 deal together
- [Grains Valley Venture Capital](https://shizune.co/investors/profile/grains-valley-venture-capital) — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Hanne Capital invest in?

Hanne Capital invests primarily in Biotechnology, Health Care and Pharmaceutical startups, most often at Series A and Series B stage. Most of the 14 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Hanne Capital?

Public channels for Hanne Capital include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Hanne Capital?

The team at Hanne Capital includes Edward Zhou (Founder & Managing Partner). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co